GSK.L vs. MA
GSK.L (GlaxoSmithKline plc) and MA (Mastercard Incorporated) are both stocks. GSK.L operates in Drug Manufacturers - General (Healthcare), while MA operates in Credit Services (Financial Services). Over the past 10 years, GSK.L returned 5.50%/yr vs 19.32%/yr for MA. At a 0.19 correlation, their price movements are largely independent.
Performance
GSK.L vs. MA - Performance Comparison
Loading charts...
Different Trading Currencies
GSK.L is traded in GBp, while MA is traded in USD. To make them comparable, the MA values have been converted to GBp using the latest available exchange rates.
Returns By Period
In the year-to-date period, GSK.L achieves a 6.65% return, which is significantly higher than MA's -12.83% return. Over the past 10 years, GSK.L has underperformed MA with an annualized return of 5.50%, while MA has yielded a comparatively higher 19.32% annualized return.
GSK.L
- 1D
- -1.29%
- 1M
- 4.74%
- YTD
- 6.65%
- 6M
- 6.89%
- 1Y
- 31.21%
- 3Y*
- 16.07%
- 5Y*
- 6.18%
- 10Y*
- 5.50%
MA
- 1D
- 0.00%
- 1M
- 1.29%
- YTD
- -12.83%
- 6M
- -8.96%
- 1Y
- -15.12%
- 3Y*
- 8.47%
- 5Y*
- 8.04%
- 10Y*
- 19.32%
GSK.L vs. MA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
GSK.L GlaxoSmithKline plc | 6.65% | 41.46% | -3.51% | 4.94% | -25.94% | 26.66% | -20.76% | 25.32% | 19.02% | -10.82% |
MA Mastercard Incorporated | -13.82% | 1.27% | 26.34% | 17.24% | 8.92% | 2.12% | 16.66% | 53.10% | 32.74% | 34.91% |
Correlation
The correlation between GSK.L and MA is 0.22, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.22 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.16 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.13 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.16 |
Correlation (All Time) Calculated using the full available price history since Jul 6, 2007 | 0.19 |
Fundamentals
GSK.L:
£77.94B
MA:
$433.70B
GSK.L:
£1.42
MA:
$17.28
GSK.L:
13.43
MA:
28.11
GSK.L:
0.30
MA:
1.64
GSK.L:
2.39
MA:
12.90
GSK.L:
4.37
MA:
64.52
GSK.L:
£32.78B
MA:
$33.94B
GSK.L:
£23.84B
MA:
$26.70B
GSK.L:
£11.56B
MA:
$21.23B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GSK.L vs. MA — Risk / Return Rank
GSK.L
MA
GSK.L vs. MA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK.L) and Mastercard Incorporated (MA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| GSK.L | MA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.91 | ||
| Sortino ratioReturn per unit of downside risk | +2.76 | ||
| Omega ratioGain probability vs. loss probability | 1.24 | 0.90 | +0.33 |
| Calmar ratioReturn relative to maximum drawdown | 1.69 | -0.74 | +2.44 |
| Martin ratioReturn relative to average drawdown | 4.14 | -1.54 | +5.68 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| GSK.L | MA | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.25 | -0.66 | +1.91 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.26 | 0.34 | -0.08 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.25 | 0.72 | -0.47 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.24 | 0.73 | -0.50 |
Drawdowns
GSK.L vs. MA - Drawdown Comparison
The maximum GSK.L drawdown since its inception was -42.39%, smaller than the maximum MA drawdown of -50.00%. Use the drawdown chart below to compare losses from any high point for GSK.L and MA.
Loading charts...
Drawdown Indicators
| GSK.L | MA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -42.39% | -50.00% | +7.61% |
Max Drawdown (1Y)Largest decline over 1 year | -18.35% | -20.39% | +2.04% |
Max Drawdown (3Y)Largest decline over 3 years | -27.42% | -22.74% | -4.68% |
Max Drawdown (5Y)Largest decline over 5 years | -42.39% | -22.74% | -19.65% |
Max Drawdown (10Y)Largest decline over 10 years | -42.39% | -34.11% | -8.28% |
Current DrawdownCurrent decline from peak | -14.20% | -19.06% | +4.86% |
Average DrawdownAverage peak-to-trough decline | -12.77% | -7.73% | -5.04% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.53% | 9.84% | -2.31% |
Volatility
GSK.L vs. MA - Volatility Comparison
The current volatility for GlaxoSmithKline plc (GSK.L) is 6.21%, while Mastercard Incorporated (MA) has a volatility of 6.57%. This indicates that GSK.L experiences smaller price fluctuations and is considered to be less risky than MA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GSK.L | MA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.21% | 6.57% | -0.36% |
Volatility (6M)Calculated over the trailing 6-month period | 18.11% | 18.25% | -0.14% |
Volatility (1Y)Calculated over the trailing 1-year period | 24.99% | 23.02% | +1.97% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 23.68% | 23.45% | +0.23% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.09% | 26.87% | -4.78% |
Dividends
GSK.L vs. MA - Dividend Comparison
GSK.L's dividend yield for the trailing twelve months is around 3.50%, more than MA's 0.67% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK.L GlaxoSmithKline plc | 3.50% | 3.51% | 4.53% | 3.84% | 5.30% | 4.93% | 5.90% | 4.45% | 5.31% | 5.99% | 4.88% | 5.77% |
MA Mastercard Incorporated | 0.67% | 0.53% | 0.50% | 0.53% | 0.56% | 0.49% | 0.45% | 0.44% | 0.53% | 0.58% | 0.74% | 0.66% |
Financials
GSK.L vs. MA - Financials Comparison
This section allows you to compare key financial metrics between GlaxoSmithKline plc and Mastercard Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
GSK.L vs. MA - Profitability Comparison
GSK.L - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a gross profit of 5.75B and revenue of 7.63B. Therefore, the gross margin over that period was 75.4%.
MA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Mastercard Incorporated reported a gross profit of 4.91B and revenue of 8.40B. Therefore, the gross margin over that period was 58.4%.
GSK.L - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported an operating income of 2.29B and revenue of 7.63B, resulting in an operating margin of 30.1%.
MA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Mastercard Incorporated reported an operating income of 4.91B and revenue of 8.40B, resulting in an operating margin of 58.4%.
GSK.L - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a net income of 1.74B and revenue of 7.63B, resulting in a net margin of 22.8%.
MA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Mastercard Incorporated reported a net income of 3.88B and revenue of 8.40B, resulting in a net margin of 46.2%.
Frequently Asked Questions
GSK.L and MA have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for GSK.L and MA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer